Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inna Tzoran

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Thrombosis and Haemostasis|April 15, 2020
Psychotropic Drugs and Outcome in Patients Receiving Anticoagulant Therapy for Venous ThromboembolismPablo Javier Marchena, Inna Tzoran, Benjamin Brenner, et al.
Thrombosis and Haemostasis|February 21, 2022
Outcome of Cancer-Associated Venous Thromboembolism Is More Favorable among Patients with Hematologic Malignancies than in Those with Solid TumorsRamón Lecumberri, Pedro Ruiz-Artacho, Inna Tzoran, et al.
The American Journal of Medicine|May 29, 2018
Arterial Ischemic Events Are a Major Complication in Cancer Patients with Venous ThromboembolismBenjamin Brenner, Behnood Bikdeli, Inna Tzoran, et al.
Annals of Hematology|April 14, 2026
Distinct cellular signatures in aplastic and intermittent phenotypes of immune effector cell-associated hematotoxicityBen Varon, Amir Grau, Noga Setter Marco, et al.
Thrombosis and Haemostasis|May 5, 2020
Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-AnalysisMichela Giustozzi, Giancarlo Agnelli, Jorge Del Toro-Cervera, et al.
British Journal of Haematology|September 15, 2025
Duration of anti-CD20 monoclonal antibody maintenance positively correlates with clinical outcomes in follicular lymphoma patients, supporting adherence to the recommended 2-year maintenance paradigmMichal Nordkin, Nashwa Fadaos, Ronit Leiba, et al.
Annals of Hematology|December 11, 2024
In patients with follicular lymphoma, delayed-onset neutropenia induced by anti-CD20 monoclonal antibodies frequently occurs during maintenance therapy and is preferentially associated with obinutuzumabNashwa Fadaos, Yossi Ben Dor, Tehila Azoulay, et al.
Haematologica|July 29, 2021
Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodiesRonit Gurion, Uri Rozovski, Gilad Itchaki, et al.
Acta Haematologica|May 23, 2024
Eosinophilic Pleocytosis in the Cerebrospinal Fluid following CAR-T Cell Therapy for Central Nervous System Lymphoma: A Case for Warning?Mayasa Abu Ata, Israel Henig, Dana Yehudai-Ofir, et al.
European Journal of Haematology|February 13, 2026
Platelet and Fibrinogen Dynamics After CAR-T Cell Therapy in Relapsed/Refractory B-Cell Lymphoma May Predict ICANS OnsetHazim Khatib, Amit Parizat, Jabour Halloun, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Thrombosis and Haemostasis|April 15, 2020
Psychotropic Drugs and Outcome in Patients Receiving Anticoagulant Therapy for Venous ThromboembolismPablo Javier Marchena, Inna Tzoran, Benjamin Brenner, et al.
Thrombosis and Haemostasis|February 21, 2022
Outcome of Cancer-Associated Venous Thromboembolism Is More Favorable among Patients with Hematologic Malignancies than in Those with Solid TumorsRamón Lecumberri, Pedro Ruiz-Artacho, Inna Tzoran, et al.
The American Journal of Medicine|May 29, 2018
Arterial Ischemic Events Are a Major Complication in Cancer Patients with Venous ThromboembolismBenjamin Brenner, Behnood Bikdeli, Inna Tzoran, et al.
Annals of Hematology|April 14, 2026
Distinct cellular signatures in aplastic and intermittent phenotypes of immune effector cell-associated hematotoxicityBen Varon, Amir Grau, Noga Setter Marco, et al.
Thrombosis and Haemostasis|May 5, 2020
Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-AnalysisMichela Giustozzi, Giancarlo Agnelli, Jorge Del Toro-Cervera, et al.
British Journal of Haematology|September 15, 2025
Duration of anti-CD20 monoclonal antibody maintenance positively correlates with clinical outcomes in follicular lymphoma patients, supporting adherence to the recommended 2-year maintenance paradigmMichal Nordkin, Nashwa Fadaos, Ronit Leiba, et al.
Annals of Hematology|December 11, 2024
In patients with follicular lymphoma, delayed-onset neutropenia induced by anti-CD20 monoclonal antibodies frequently occurs during maintenance therapy and is preferentially associated with obinutuzumabNashwa Fadaos, Yossi Ben Dor, Tehila Azoulay, et al.
Haematologica|July 29, 2021
Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodiesRonit Gurion, Uri Rozovski, Gilad Itchaki, et al.
Acta Haematologica|May 23, 2024
Eosinophilic Pleocytosis in the Cerebrospinal Fluid following CAR-T Cell Therapy for Central Nervous System Lymphoma: A Case for Warning?Mayasa Abu Ata, Israel Henig, Dana Yehudai-Ofir, et al.
European Journal of Haematology|February 13, 2026
Platelet and Fibrinogen Dynamics After CAR-T Cell Therapy in Relapsed/Refractory B-Cell Lymphoma May Predict ICANS OnsetHazim Khatib, Amit Parizat, Jabour Halloun, et al.
Pageof 3